Compare Natco Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PANACEA BIOTECH NATCO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 15.0 10.3 145.4% View Chart
P/BV x 3.0 2.2 134.9% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 NATCO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
PANACEA BIOTECH
Mar-19
NATCO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs849354 240.1%   
Low Rs557138 403.0%   
Sales per share (Unadj.) Rs573.874.6 769.6%  
Earnings per share (Unadj.) Rs176.06.7 2,635.1%  
Cash flow per share (Unadj.) Rs198.215.5 1,279.0%  
Dividends per share (Unadj.) Rs6.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs842.757.2 1,473.1%  
Shares outstanding (eoy) m36.5061.25 59.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.23.3 37.1%   
Avg P/E ratio x4.036.8 10.8%  
P/CF ratio (eoy) x3.515.9 22.4%  
Price / Book Value ratio x0.84.3 19.4%  
Dividend payout %3.60-   
Avg Mkt Cap Rs m25,66015,061 170.4%   
No. of employees `0005.02.3 214.2%   
Total wages/salary Rs m3,5591,471 242.0%   
Avg. sales/employee Rs Th4,225.31,973.6 214.1%   
Avg. wages/employee Rs Th718.0635.6 113.0%   
Avg. net profit/employee Rs Th1,295.9176.8 733.0%   
INCOME DATA
Net Sales Rs m20,9454,567 458.6%  
Other income Rs m1,30245 2,906.3%   
Total revenues Rs m22,2474,612 482.4%   
Gross profit Rs m7,9482,030 391.6%  
Depreciation Rs m810540 150.0%   
Interest Rs m1931,048 18.4%   
Profit before tax Rs m8,247486 1,696.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,82377 2,364.5%   
Profit after tax Rs m6,424409 1,570.3%  
Gross profit margin %37.944.4 85.4%  
Effective tax rate %22.115.9 139.4%   
Net profit margin %30.79.0 342.4%  
BALANCE SHEET DATA
Current assets Rs m23,4722,415 972.1%   
Current liabilities Rs m7,2879,077 80.3%   
Net working cap to sales %77.3-145.9 -53.0%  
Current ratio x3.20.3 1,211.0%  
Inventory Days Days9265 141.7%  
Debtors Days Days8871 124.4%  
Net fixed assets Rs m18,6488,333 223.8%   
Share capital Rs m36561 595.4%   
"Free" reserves Rs m34,5253,443 1,002.8%   
Net worth Rs m30,7603,504 877.9%   
Long term debt Rs m0461 0.0%   
Total assets Rs m43,03113,755 312.8%  
Interest coverage x43.71.5 2,987.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.3 146.6%   
Return on assets %15.410.6 145.1%  
Return on equity %20.911.7 178.9%  
Return on capital %27.438.7 70.9%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m11,5361,203 958.9%   
Fx outflow Rs m2,939467 629.8%   
Net fx Rs m8,597736 1,167.5%   
CASH FLOW
From Operations Rs m6,6881,049 637.7%  
From Investments Rs m-6,122-54 11,443.0%  
From Financial Activity Rs m-509-1,011 50.3%  
Net Cashflow Rs m66-20 -335.0%  

Share Holding

Indian Promoters % 52.0 74.5 69.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.6 1,306.7%  
FIIs % 16.6 1.3 1,279.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 23.6 110.2%  
Shareholders   25,395 10,259 247.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 19, 2019 03:37 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - GLENMARK PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS